Defective insulin signaling and mitochondrial dynamics in diabetic cardiomyopathy  by Westermeier, Francisco et al.
Biochimica et Biophysica Acta 1853 (2015) 1113–1118
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbamcrReviewDefective insulin signaling and mitochondrial dynamics in
diabetic cardiomyopathyFrancisco Westermeier a, Mario Navarro-Marquez a, Camila López-Crisosto a, Roberto Bravo-Sagua a,
Clara Quiroga a, Mario Bustamante a, Hugo E. Verdejo b, Ricardo Zalaquett b, Mauricio Ibacache c,
Valentina Parra a,d,e, Pablo F. Castro b, Beverly A. Rothermel d,e, Joseph A. Hill d,e, Sergio Lavandero a,d,e,⁎
a Advanced Center for Chronic Diseases (ACCDiS), Faculty of Chemical & Pharmaceutical Sciences & Faculty of Medicine, University of Chile, Santiago, Chile
b Advanced Center for Chronic Diseases (ACCDiS), Faculty of Medicine, Pontiﬁcal Catholic University of Chile, Santiago, Chile
c Anesthesiology Division, Faculty of Medicine, Pontiﬁcal Catholic University of Chile, Santiago, Chile
d Internal Medicine Division of Cardiology, Dallas, TX, USA
e Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX, USAAbbreviations:DCM,Diabeticcardiomyopathy;T2DM,
ventricular; CAD, Coronary artery disease; HFD, High fat-d
receptor substrate 1; CIRKO, Cardiomyocyte-speciﬁc kn
Mnf1, Dynamin-related GTPasemitofusin 1;Mnf2, Dynam
Opa-1, Optic atrophy protein 1; IMM, Innermitochondrial
chondrial membrane; Fis1,Mitochondrial ﬁssion 1 protein
1; ROS, Reactive oxygen species; SOD, Superoxide dismuta
β-N-acetylglucosamine modiﬁcation; HF, Heart failure;
rapamycin; NFκB, Nuclear factor kappa-light-chain-enha
Serine/threonine kinase PTEN-induced putative kinase 1; P
5′ AMP-activated protein kinase; Drp1-CKO, Cardiomyocyte
Type 1 diabetes mellitus; LAMP1, Lysosomal-associated m
receptor substrate 2; CIRS12KO, Cardiomyocyte-speciﬁc del
⁎ Corresponding author at: Advanced Center for Chron
Chemical & Pharmaceutical Sciences & Faculty of Medicin
Santiago, Chile. Tel.: +56 2 29782919; fax: +56 2 29782
E-mail address: slavander@uchile.cl (S. Lavandero).
http://dx.doi.org/10.1016/j.bbamcr.2015.02.005
0167-4889/© 2015 Elsevier B.V. All rights reserved.a b s t r a c ta r t i c l e i n f oArticle history:
Received 18 October 2014
Received in revised form 21 January 2015
Accepted 8 February 2015
Available online 14 February 2015
Keywords:
Insulin signaling
Diabetic cardiomyopathy
Mitochondrial dynamicsDiabetic cardiomyopathy (DCM) is a common consequence of longstanding type 2 diabetesmellitus (T2DM) and
encompasses structural, morphological, functional, and metabolic abnormalities in the heart. Myocardial energy
metabolism depends on mitochondria, which must generate sufﬁcient ATP to meet the high energy demands of
the myocardium. Dysfunctional mitochondria are involved in the pathophysiology of diabetic heart disease. A
large body of evidence implicates myocardial insulin resistance in the pathogenesis of DCM. Recent studies
show that insulin signaling inﬂuencesmyocardial energymetabolism by impacting cardiomyocytemitochondri-
al dynamics and function under physiological conditions. However, comprehensive understanding of molecular
mechanisms linking insulin signaling and changes in the architecture of the mitochondrial network in diabetic
cardiomyopathy is lacking. This review summarizes our current understanding of howdefective insulin signaling
impacts cardiac function in diabetic cardiomyopathy and discusses the potential role ofmitochondrial dynamics.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Diabetic cardiomyopathy (DCM) is deﬁned as the presence of left
ventricular (LV) dysfunction beyond that which can be accounted for
by arterial hypertension, coronary artery disease (CAD) or evidence of
any other structural cardiac disease in individuals with diabetes [1,2].
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9192.been proposed to contribute to the development of DCM [3]. Because
mitochondria are the major source of ATP to meet the energy demands
of the heart, it has been proposed that mitochondrial dysfunction is an
underlying cause of metabolic disorders and insulin resistance-
associated heart disease [4]. Extensive experimental and clinical evi-
dence indicates that mitochondrial dynamics (fusion, ﬁssion and
mitophagy) are essential for mitochondrial quality control and
sustained function in several tissues [5] including the cardiovascular
system [6,7]. In addition, prolonged hyperglycemia and insulin resis-
tance in individuals with T2DM can lead to dramatic changes in cardiac
mitochondrial dynamics and function [8–10]. Studies by Battiprolu et al.
showed that mice developed myocardial insulin resistance in response
to high fat-diet (HFD) characterized by a down-regulation of IRS1 activ-
ity, decreased AKT signaling, and a shift from glucose to fatty acid (FA)
utilization [11]. Micewith cardiomyocyte-selective ablation of the insu-
lin receptor (CIRKO) showed defects in FA and pyruvate metabolism
and reduced tricarboxylic acid ﬂux associated with mitochondrial
uncoupling. Thus, altered insulin signaling in the heart may contribute
directly to mitochondrial dysfunction in the setting of obesity and
T2DM [4]. Our group recently demonstrated a link between insulin
and the regulation of mitochondrial dynamics, particularly mitochon-
drial fusion, in neonatal rat cardiomyocytes [12], raising new questions
regarding the interplay amongmechanisms affecting the architecture of
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the available evidence that links insulin signaling to DCM and discuss
the potential functional roles of mitochondrial dynamics.
2. Diabetic cardiomyopathy and mitochondrial dynamics in the
heart
Myocardial energy deﬁciency is closely related to the initiation and
progression of various cardiac pathologies, such as those observed
during insulin resistance and T2DM [13,14]. Under normal physiological
conditions, the heart utilizes energy from substrates (FA and carbohy-
drates) based on metabolic demand and availability [15]; however, in
the setting of insulin resistance, themyocardium's ability to use glucose
as an energy source is reduced [16,17]. This change in substrate prefer-
ence plays a critical role in the pathophysiology of DCM [11,18].
Mitochondria are highly abundant and represent 30% of cardiac cell
volume, generating more than 90% of the intracellular ATP consumed
by the heart [15,19]. Thus, many studies are currently focused on mito-
chondrial dysfunction as a causative factor in metabolic disorders and
insulin resistance-associated heart diseases [20,21].
In mammalian cells the mitochondria are dynamic organelles that
continuously change their morphology through fusion and ﬁssion
events in response to intracellular circumstances, and changes in the
balance of these processes have been implicated in different biological
events such as cell division, apoptosis, autophagy, and metabolism [6,
22]. Nonetheless, it is important to consider that evidence available in
the literature about cardiac mitochondrial dynamics differs according
to the type of cardiac cells analyzed. For example, mitochondria are
distributed throughout the cytoplasm in a reticular network and are un-
restricted in their movements in neonatal cardiomyocytes or immortal
cardiac cell lines (H9c2, HL-1 cells). Conversely, in adult cardiomyocytes
themitochondria are located under the sarcolemma, around nuclei and
between myoﬁbrils, providing enough ATP for muscle contraction;
however their ability tomove is limited due to these cellular constraints
[6,19]. Thus, mitochondrial division is estimated to only occur at an ex-
tremely low frequency in adult cardiomyocytes under physiological
conditions [23]. However, despite the evidence mentioned above the
proteins implicated in mitochondrial dynamics are present in the
adult heart, suggesting that adult cardiac mitochondria have retained
their ability to undergo fusion, ﬁssion and mitophagy (mitochondrial
degradation), which are key processes associated with quality control
of mitochondria, mitochondrial turnover and mitochondrial homeosta-
sis in adult cardiomyocytes [19]. However, this is not the only task
carried out by mitochondrial dynamics [5]. Recent studies have linked
mitochondrial dynamics to the balance between energy demands and
nutrient supply, suggesting that changes in mitochondrial morphology
can act as a mechanism for energetic adaptation to changing cardiac
metabolic necessities [24]. Indeed, alterations in mitochondrial struc-
ture and function have been linked to cardiovascular diseases [6] includ-
ing DCM [25].
Despite the apparent correlation between the dysregulation of mito-
chondrial dynamics andmyocardial energy deﬁciency, the precisemech-
anism of how this dysregulation contributes to the pathogenesis of DCM
is still unclear. Moreover, current understanding of the importance ofmi-
tochondrial dynamics in the heart seems to contradict the long-standing
paradigm in the mitochondrial ﬁeld that cardiac mitochondria are rela-
tively static [26]. Although recent in vivo observations support the
presence of morphological changes, the question that still remains is
whether these changes are cause or consequence of disease progression.
2.1. Diabetic cardiomyopathy and mitochondrial ﬁssion/fusion in the heart
In mammalian cells, the main regulators of mitochondrial fusion are
the dynamin-related GTPases mitofusins (Mnf1 and Mfn2) specialized
proteins localized on the outer mitochondrial membrane, and optic at-
rophy protein 1 (Opa-1), a protein localized on the inner mitochondrialmembrane (IMM). On the other hand, the mitochondrial ﬁssion 1 pro-
tein (Fis1), localized on the outer mitochondrial membrane (OMM),
and the cytoplasmic GTPase dynamin related protein 1 (Drp1) are
involved in mitochondrial ﬁssion [24,27] (Fig. 1A).
Several studies have indicated that mitochondrial quality control
plays a pivotal role in protecting the heart against stress, although the
presence of ﬁssion and fusion has not been well documented in adult
cardiomyocytes [26], extremely well organized cells in which mito-
chondrial movements are greatly restricted [19]. In this sense, initial
studies were done with neonatal cardiomyocytes or with immortalized
cardiac cell lines (H9c2, HL-1) [28,29] in which the mitochondrial net-
work does not directly reﬂect that of an adult cardiomyocyte [19].
Chen et al. reported that the fusion/ﬁssion cycle would last 14–16 days
in adult cardiomyocytes, being slower than that seen in neonatal
cardiomyocytes [30], suggesting that mitochondrial dynamics is a pro-
cess that depends on the cardiomyocyte cell architecture. Studies in
non-cardiac cells [31–35] have shown that low expression of fusion
proteins is associatedwithmitochondrial network fragmentation. How-
ever, Papanicolau et al. showed that mice harboring a cardiomyocyte-
speciﬁc knockout of Mfn2 exhibited larger mitochondria [36]. This
was also observed in Opa1 (+/−) mice, which accumulated large clus-
ters of fused mitochondria with altered cristae [37]. Cardiomyocyte-
speciﬁc Mfn1-null mice showed fragmentation of their mitochondrial
network [38] andmicewith an adult cardiomyocyte-speciﬁc condition-
al ablation of Mfn1/Mfn2 together developed a fragmented mitochon-
drial network and progressed to dilated cardiomyopathy [30]. Thus,
mitochondrial dynamics is a complex process in the adult heart and
may depend upon the speciﬁc cell architecture. Moreover, in terms of
cardiac contractile function, increases in mitochondrial volume may di-
rectly impact the force developed by myoﬁbrils [39], suggesting a direct
link between mitochondrial morphology and cardiac contractile func-
tion. On the one hand, enhanced mitochondrial fragmentation may
lead to cardiac disorders [24]; on the other hand, Ishihara et al. have
shown thatmitochondrial ﬁssion is required for neonatal cardiomyocyte
development, participating in the formation of highly organized myoﬁ-
brils andmaintenance of uniformly activemitochondria withmitochon-
drial DNA (mtDNA) nucleoids in cardiomyocytes [40], suggesting that
mitochondrial ﬁssion is a key process during heart development.
Studies speciﬁcally addressing the direct relationship between
ﬁssion and fusion of cardiac mitochondrial and insulin resistance and
T2DM are limited. However, we know that a major contributory factor
linked to the onset of DCM is hyperglycemia-induced oxidative stress
(Fig. 1B). In this context, in vitro data from Yoon's group suggest that
hyperglycemia induces mitochondrial fragmentation in neonatal rat
ventricular myocytes (H9c2 cells) [41]. Furthermore, in the same
model Yu et al. also demonstrated that sustained hyperglycemia induces
mitochondrial ﬁssion together with mitochondrial reactive oxygen
species (ROS) production, which in turn promotes activation of a
proapoptotic pathway [42]. These pathological changes could be
prevented by transfecting the cells with a dominant-negative form of
Drp1, DrpK38A, suggesting that mitochondrial fragmentation and
dysfunction in the setting of hyperglycemia is Drp1-dependent [42].
Similarly, in a recent article, Watanabe et al. showed that Drp1 and
ROS act synergistically to promote mitochondrial dysfunction and in-
hibit insulin signal transduction in H9c2 cells [43]. This effect could be
partially reversed when these cells were treated with the superoxide
dismutase (SOD) mimetic TMPyP [43]. In a different, but related
model, Makino et al. showed mitochondrial fragmentation in coronary
endothelial cells from murine diabetic hearts that was associated with
reduced levels of Opa-1 and increased levels of Drp1 [44]. Studies in
models of T2DM suggest that insulin resistance might contribute to
reduced myocardial recovery after ischemia [45]. Interestingly, pre-
treatment of adult rat cardiomyocytes with Mdivi-1 (pharmacological
inhibitor of Drp1) reduced cell death and protected the heart from
ischemia/reperfusion injury [46]. Transfection of neonatal rat cardio-
myocyte with Drp1K38A to inhibit ﬁssion was likewise protective [47].
Fig. 1. Mitochondrial dynamics in the heart. A) Insulin induces mitochondrial fusion in cardiomyocytes. Fusion of the outer mitochondrial membrane (OMM) is carried out by the
dynamin-relatedGTPases,mitofusins 1 and2 (Mnf1/2). Optic atrophy protein 1 (Opa-1) participates in fusion of the innermitochondrialmembrane (IMM). Both processes increase cristae
density, promotingmitochondrialmetabolism. B)Hyperglycemia and reactive oxygen species (ROS) impairmitochondrial fusion associatedwith reduced levels of Opa-1 andMfn2. These
processes also promotemitochondrial ﬁssion involving themitochondrial ﬁssion 1 protein (Fis1) and the dynamin related protein 1 (Drp1), triggering cardiac mitochondrial dysfunction.
Mitochondrial damage can activate selective mitophagy that involves Drp1-mediated ﬁssion, activation of the PTEN-induced putative kinase 1 (Pink1) and the E3 ubiquitin ligase Parkin.
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function, and whether fusion is protective of cardiac function, both re-
main unclear. However, recent studies by Montaigne et al., postulate
that hyperglycemia may be a major driver of both mitochondrial dys-
function and mitochondrial network fragmentation in the human dia-
betic heart [10] (Fig. 1B). They demonstrated that declines in
myocardial function in the transition fromobesity to T2DMare likely re-
lated to declines in cardiac mitochondrial function rather than a direct
consequence of insulin resistance, as impaired mitochondrial function
and dynamics (as well as LV contractile dysfunction) are observed in di-
abetic patients, but not in obese patients during early stages of insulin
resistance. These effects in humanhearts were associatedwith fragmen-
tation of the mitochondrial network and decreased expression of the
Mnf1, but no signiﬁcant alteration of Fis1 andDrp1 [10]. However, Mon-
taigne et al., cannot rule out the possibility that posttranslational
modiﬁcations such as glycation and O-linked-β-N-acetylglucosamine
modiﬁcation (O-Glc-NAcylation) could modulate the function of pro-
teins involved in mitochondrial dynamics reported in human cardiac
myocytes under high-glucose conditions [48,49]. Interestingly, rat neo-
natal cardiomyocytes maintained under high glucose concentrations
have lower Opa-1 levels and amore fragmentedmitochondrial network
[50] similar to the pattern observed in myocardial biopsies of T2DM
patients [10]. Moreover, decreased levels of Opa-1 were also observed
in biopsies of HF patients [51].
Our group recently demonstrated a link between insulin and the
regulation ofmitochondrial dynamics, particularlymitochondrial fusion
in cardiomyocytes [12] (Fig. 1A). Insulin treatment of cardiomyocytes
increased the levels of Opa-1, promotedmitochondrial fusion, increased
mitochondrial membrane potential, and elevated both intracellular ATP
levels and oxygen consumption in rat neonatal cardiomyocytes. How-
ever, the ability of insulin to inﬂuence metabolism was impaired in
cells deﬁcient of Mfn2 or Opa-1 [12]. Thus, these data strongly suggestthat insulin stimulation enhances mitochondrial function in neonatal
cardiomyocytes through a novel regulatory pathway involved in the
control of Opa-1 protein levels that is mediated by AKT, mTOR, and
NFκB. Taken altogether, this reinforces the concept that mitochondrial
fusion is essential in cardiac homeostasis regulating different processes
such as mitochondrial morphology, cardiac respiration, and contractile
function in adult cardiomyocytes [30]. Whether these changes cause
mitochondrial remodeling and how they affect the function of mito-
chondria during DCM remain to be elucidated.
2.2. Diabetic cardiomyopathy and mitophagy in the heart
Autophagy is an intracellular catabolic pathway in which proteins
and organelles are delivered to and degraded in lysosomes allowing
the cell to maintain energy homeostasis under conditions of starvation
or nutrient deprivation [52]. Selective autophagic degradation of mito-
chondria is termed mitophagy [53–55]. Although mitochondria may
be degraded during nonselective autophagy, it is now clear that func-
tional status of mitochondria degraded during generalized autophagy
may be very different from the functional status of mitochondria
targeted for selective degradation bymitophagy [25,53]. Themitochon-
drial ﬁssion can facilitate removal of damaged mitochondrial compo-
nents by partitioning them to a daughter mitochondrion that can then
be targeted and removed by mitophagy [56]. Disruption of the mito-
chondrial quality control mechanisms associated with the interplay be-
tween mitochondrial dynamics and mitophagy in different tissues [56]
has also been linked to various cardiac diseases [7].
Emerging key players in the regulation of mammalian mitophagy are
the serine/threonine kinase PTEN-induced putative kinase 1 (Pink1) and
the E3 ubiquitin ligase Parkin, which selectively promote the degradation
of impaired mitochondria [57] (Fig. 1B). Parkin-deﬁcient (Parkin −/−)
mice showed impaired mitophagy and accumulation of dysfunctional
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[58]. Pink1 appears to play a critical role in cardiac biology, as Pink1
knockoutmice (Pink−/−) exhibit cardiac hypertrophywithdefectivemi-
tochondrial function and increased myocardial injury in response to is-
chemia/reperfusion [59,60]. Moreover, cardiomyocyte-speciﬁc deletion
of PTEN leads to the loss of Pink1-AMPK signaling, development of
cardiac hypertrophy and disruption of autophagic ﬂux in the heart
[61]. Although Parkin-inducedmitophagy has been shown to be depen-
dent on the kinase activity of Pink1, the ubiquitin ligase activity of
Parkin, and Drp1-mediated mitochondrial ﬁssion [62,63], a full under-
standing of the regulatory mechanisms involved in these processes in
the heart has yet to emerge. However, recently, mitochondrial dysfunc-
tion and dilated cardiomyopathy associated with defective mitophagy
[64] and autophagy [65] were reported in mice with hearts deﬁcient
for Mfn2.
In the heart, under both physiological and pathological conditions,
several reports have associated mitophagy with cardiac homeostasis
and myocardial protection [25,58,66–71]. Narendra et al. described in
HeLa cells the ﬁrst molecular link between mitochondrial membrane
depolarization and autophagy by identifying Parkin as a mediator of
mitophagy downstream of mitochondrial depolarization [57]. In the
context of our current discussion, the inhibition of Parkin-mediated
autophagy by cytosolic p53was associatedwithmitochondrial dysfunc-
tion in the mouse heart [69]. Interestingly, a recent study showed that
cardiac and mitochondrial function was normal in 3-month-old
Parkin-deﬁcient (Parkin −/−) heart. Nevertheless, Parkin −/− mice
were much more sensitive to myocardial infarction compared with
wild typemice, and damages were associated with increased disorgani-
zation of themitochondrial network [58]. However, by electronmicros-
copy the same research group reported that 6-month-old (Parkin −/−)
micehad abnormalmitochondria containing electron-densemacromol-
ecules, suggesting that clearance occurs at a slower rate leading to anac-
cumulation of abnormal mitochondria in cardiomyocytes with age [70].
Drp1 plays a role in mediating Parkin-induced mitophagy by
Bnip3 in adult rat cardiomyocytes [72] and, as we previously men-
tioned, pharmacological suppression of Drp1 with Mdivi-1 attenu-
ates myocardial injury in response to ischemia/reperfusion and
reduces cell death in adult rat cardiomyocytes [46]. These results
have led to a general belief that mitochondrial fusion is protective.
However, a recent study carried out by Ikeda et al., using an interest-
ing model of cardiomyocyte-speciﬁc Drp1 knockout (Drp1-CKO)
mice showed that downregulation of Drp1 enhanced myocardial in-
jury in response to ischemia/reperfusion. Moreover, Drp1-CKO mice
exhibited mitochondrial dysfunction, myocardial cell death, heart
failure and premature death, suggesting that endogenous Drp1
plays a key role in mediating mitophagy and maintaining mitochon-
drial function in response to stress in the heart [73]. In parallel,
Sesaki's group also reported lethal heart defects and decreased mito-
chondrial respiration in mice lacking cardiac Drp1. However, they
described a Parkin-independent mitophagy associatedwith accumu-
lation of p62 and ubiquitinated proteins in Drp1KO cardiomyocytes,
highlighting the role of Parkin in mitochondrial homeostasis in the
absence of cardiac mitochondrial division [74].
Several studies using models of type 1 diabetes mellitus (T1DM)
[75–78] or T2DM [79–81] have suggested that the inhibition of autoph-
agy may contribute to the development of DCM; however, its potential
protective role in diabetic cardiac injury remains unclear [25]. The func-
tional status of general autophagy may not necessarily reﬂect the activ-
ity of selective mitophagy. In this way, Xu et al. showed that autophagy
is inhibited in the diabetic heart as early as 3 weeks after streptozotocin
injection, while mitophagy is not reduced until more advanced stages
[78]. Intriguingly, the hearts of mice deﬁcient in Beclin 1 or Atg16 still
retainedmitophagic activity even under diabetic conditions, as assessed
by the expression and mitochondrial localization of Pink1, Parkin, and
the lysosomal-associated membrane protein 1 (LAMP1) [78]. These re-
sults suggest that in a model of T1DM reducing autophagy may be anadaptive response, whereas up-regulation of other alternative au-
tophagic activities, such as mitophagy, may likewise help preserve
cardiac function. Nevertheless, the functional role of mitophagy
and the speciﬁc mechanisms regulating its activity in the diabetic
heart remain to be determined.
Recent studies have suggested an important role for insulin signaling
in the regulation of myocardial autophagy [82,83]. Mice with
cardiomyocyte-speciﬁc deletion of both IRS1 and IRS2 (CIRS12KO)
showed unrestrained autophagy in cardiomyocytes, which contributed
to myocyte loss, heart failure, and premature death. Moreover,
CIRS12KO mice exhibited increased apoptosis and mitochondrial dys-
function, which were not reversed when autophagic ﬂux was normal-
ized [83]. Moreover, insulin administration to streptozotocin-induced
diabetic rats [82] and cultured cardiomyocytes in vitro following
nutrient withdrawal [83], suppressed autophagic signaling. On the
other hand, the hearts of mice with reduced PI3K/AKT signaling ex-
hibited increased indices of autophagy and reduced accumulation
of damaged organelles [84]. Conversely, constitutive activation of
PI3K/AKT signaling inhibited basal cardiac autophagic ﬂux [84,85].
However, even though this evidence provides insight into the dynamic
regulation of cardiac autophagy by insulin, its role in mitophagy
remains to be established.3. Conclusion and open questions
T2DMand insulin resistance have been implicated in the pathophys-
iology of DCM and also increase the risk of developing cardiovascular
complications [3]. Extensive evidence suggests a mechanistic link be-
tween insulin resistance and altered substrate metabolism in DCM in-
volving a shift from glucose to FA utilization by the cardiomyocyte
[11]. Mitochondria play a central role in meeting the energy demands
of the heart under physiological conditions, and new insights are
emerging that place mitochondrial dysfunction as a key event contrib-
uting to development of DCM [10]. Recent evidence demonstrates that
insulin can promote mitochondrial fusion, increase mitochondrial
membrane potential, and elevate both intracellular ATP levels and
oxygen consumption in rat neonatal cardiomyocytes [12]; nonetheless,
there are many open questions that remain to be addressed regarding
the impact of insulin on mitochondrial dynamics in the adult heart, be-
cause differences in the cell architecture amongneonatal cardiomyocytes,
immortalized cell lines and adult cardiomyocytes are key for energy
transfer and communication between organelles [19]. For the same rea-
son, what is the impact of insulin signaling (protective/detrimental) on
mitochondrial dynamics in DCM? Mitochondrial ﬁssion has been asso-
ciated withmetabolic cardiac disorders and in contrast, fusion is gener-
ally considered beneﬁcial [24]. However, a recent study indicates that
chronic downregulation of Drp1 induces elongation of mitochondria,
mitochondrial dysfunction, heart failure and premature death in
mice [73]. So, is there a critical balance between fusion/ﬁssion re-
quired for both preservation of mitochondrial function and mainte-
nance of cellular homeostasis in the heart? How is this balance altered
in DCM?
Recent studies have suggested an important role for insulin signaling
in the regulation ofmyocardial autophagy [82,83]. Moreover, the inhibi-
tion of cardiac autophagy reported in different models of diabetes may
contribute to the development of DCM [25]. Nonetheless, the functional
status of general autophagy may not necessarily reﬂect the activity of
selective mitophagy. A recent study carried out by Kageyama et al. sug-
gests that Drp1 can promote the delivery of mitochondria to lysosomes
independent of Parkin [74]. How are general autophagy and selective
mitophagy differentially regulated in DCM? Answers to these questions
will help elucidate the complex interplay between insulin signaling and
mitochondrial dynamics in DCM and will lay the foundation for the de-
velopment and application of new drugs and therapies targeted toward
preventing or treating DCM.
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